Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;22(11):151-161.
doi: 10.1007/s11882-022-01041-2. Epub 2022 Sep 10.

Narrative Review of the Role of Patient-Reported Outcomes and Inhaler Handling Errors in the Control of Asthma and COPD

Raúl De Simón Gutiérrez  1 , Raúl Piedra Castro  2
Affiliations
Review

Narrative Review of the Role of Patient-Reported Outcomes and Inhaler Handling Errors in the Control of Asthma and COPD

Raúl De Simón Gutiérrez et al. Curr Allergy Asthma Rep. 2022 Nov.

Abstract

Purpose of review: Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory diseases that remain uncontrolled in many patients, despite the wide range of therapeutic options available. This review analyzes the available clinical evidence on 3 budesonide/formoterol DPI devices, Spiromax®, Turbuhaler®, and Easyhaler®, in terms of patient-reported outcomes (PROs), inhaler errors, and asthma and COPD control.

Recent findings: The effectiveness of dry powder inhalers (DPI) depends largely on the device and the patient's inhaler technique. Equally important are the patient's perception of the inhaler and adherence. Given the high burden of these diseases, it is important that efforts be made to select the best DPI for each patient and to analyze the impact of these variables to help improve the health and quality of life of our patients. This review provides a comprehensive overview of the present knowledge about PROs, inhaler handling errors, and asthma and COPD control achieved by Spiromax®, Turbuhaler®, and Easyhaler®.

Keywords: Asthma; COPD; Dry powder inhalers; Inhaler error; Patient-reported outcomes; Spiromax.

PubMed Disclaimer

Conflict of interest statement

The authors of this review have received funding from Laboratorios Bial.

Similar articles

See all similar articles

References

    1. World Health Organization (WHO). Chronic diseases and their common risk factors. https://apps.who.int/iris/handle/10665/43314. Accessed 20 Dec 2021.
    1. GINA. GINA main report - Global Initiative for Asthma - GINA. Updated 2021. https://ginasthma.org/gina-reports/. Accessed 20 Dec 2021.
    1. GOLD. Global strategy for prevention, diagnosis and management of COPD. 2022. https://goldcopd.org/2022-gold-reports-2/. Accessed 20 Dec 021.
    1. Chrystyn H, Lavorini F. The dry powder inhaler features of the Easyhaler that benefit the management of patients. Expert Rev Respir Med. 2020;14(4):345–351. doi: 10.1080/17476348.2020.1721286. - DOI - PubMed
    1. Miravitlles M, Sliwinski P, Rhee CK, Costello RW, Carter V, Tan JHY, et al. Predictive value of control of COPD for risk of exacerbations: an international, prospective study. Respirology. 2020;25(11):1136–1143. doi: 10.1111/resp.13811. - DOI - PubMed

MeSH terms

Substances